uniQure shares plunged after four-year data for Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. While 48-month TFC data remained encouraging, the cUHDRS effect was not statistically significant. Investors are now focused on FDA review and whether the therapy’s earlier benefits can demonstrate durability over time.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.